Nyrada Inc : Cholesterol-Lowering Program Update

Nyrada Inc (ASX: NYR), a drug development company specialising in novel small molecule drugs to treat cardiovascular and neurological diseases, today announced that while the Company’s cholesterol-lowering drug candidate returned no unusual safety signals in all but one key study, due to an adverse signal observed in a Good Laboratory Practice (GLP) toxicology study, the Company’s drug candidate will not be taken forward into the planned Phase I/IIa clinical trial.